NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. The company's website is www.neurocrine.com.

Neurocrine operates a commercial portfolio of FDA-approved products anchored by INGREZZA (valbenazine), a highly selective VMAT2 inhibitor approved for tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA generated net product sales of $2.51 billion in 2025, representing a significant portion of total revenues. The company also commercializes CRENESSITY (crinecerfont), a first-in-class CRF1 receptor antagonist approved for classic congenital adrenal hyperplasia, which achieved $301.2 million in net product sales during its first full year of launch in 2025. Additionally, Neurocrine markets elagolix for endometriosis and uterine fibroids in collaboration with AbbVie Inc., which retains global commercialization rights.

The company maintains a specialized sales force of approximately 600 professionals across the United States focused on neurology, psychiatry, long-term care, and rare diseases. Neurocrine distributes INGREZZA through a limited specialty network including specialty pharmacy providers, wholesale distributors, and specialty distributors, while CRENESSITY is sold through a single specialty pharmacy provider reflecting its rare disease focus.

Neurocrine's pipeline comprises a diversified portfolio of compounds in mid- to late-phase development, including late-stage candidates osavampator for major depressive disorder and direclidine for schizophrenia, with initial topline data expected in 2027. The company also advances early-stage programs across psychiatry, neurology, endocrinology, and metabolic diseases, including next-generation VMAT2 inhibitors designed for long-acting injectable administration and novel CRF receptor modulators. The company outsources manufacturing to third-party manufacturers while maintaining internal research and development capabilities in medicinal chemistry, biologics, and translational sciences. Neurocrine's intellectual property portfolio includes 22 issued FDA Orange Book-listed U.S. patents for INGREZZA expiring between 2027 and 2040, and four issued FDA Orange Book-listed U.S. patents for CRENESSITY expiring between 2035 and 2041.